基于hdac的雙靶點抗腫瘤藥物研究進展doc(存儲版)
【正文】 J］. Curr Med Chem, 2008, 15(5): 422432.[2] Wilhelm S, Carter C, Lynch M, et al. Discovery and development of sorafenib: a multikinase inhibitor for treating cancer［ J］. Nat Rev Drug Discov, 2006, 5(10): 835844. doi: [3] Groselj B, Sharma NL, Hamdy FC, et al. Histone deacetylase inhibitors as radiosensitisers: effects on DNA damage signaling and repair［ J］. Br J Cancer, 2013, 108(4): 748754. doi: [4] Bertrand P. Inside HDAC with HDAC inhibitors［ J］. Eur J Med Chem, 2010, 45(6): 20952116. doi: [5] Delcuve GP, Khan DH, Davie JR. Targeting class I histone deacetylases in cancer therapy［ J］. Expert Opin Ther Targets, 2013, 17(1): 2941. doi: [6] Paris M, Porcelloni M, Binaschi M, et al. Histone deacetylase inhibitors: from bench to clinic［ J］. J Med Chem, 2008, 51(6): 15051529. doi: [7] Qiu T, Zhou L, Zhu W, et al. Effects of treatment with histone deacetylase inhibitors in solid tumors: a review based on 30 clinical trials［ J］. Future Oncol, 2013,:[8] New M, Olzscha H, La Thangue NB. HDAC inhibitorbased therapies: Can we interpret the code［ J］. Mol Oncol, 2012, 6(6): 637656. doi: [9] Minucci S, Pelicci PG. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer［ J］.Nat Rev Cancer, 2006, 6(1): 3851. doi: [10] CHOBANIAN N H，GREENBERG V L，GASS J M， et al． Histone deacetylase inhibitors enhance paclitaxelinduced cell death in ovarian cancer cell lines independent of p53 status［J］． Anticancer Res，2004，24 ( 2B) : 539 － 546．[11] ZUCO V，DECESARE M，CINCINELLI R，et al． Synergistic antitumor effects of novel HDAC inhibitors and paclitaxel in vitro and in vivo［J］． PloS one， 2011， 6( 12) : e29085．[12] ZHANG X，ZHANG J，TONG L， et al． The discovery of colchicineSAHA hybrids as a new class of antitumor agents［J］． Bioorg Med Chem， 2013， 21( 11) : 3240 －3244．[13] GU J J，SANTIAGO L，MITCHELL B S． Synergy between imatinib and mycophenolic acid in inducing apoptosis in cell lines expressing BcrAbl［J］． Blood，2005， 105( 8) : 3270 － 3277．[14] CHEN L，WILSON D， JAYARAM H N， et al． Dual inhibitors of inosine monophosphate dehydrogenase and histone deacetylases for cancer treatment［J］． J Med Chem， 2007， 50( 26) : 6685 － 6691．[15] PANKIEWICZ K W，LESIAKWATANABE K B，WATANABE K A， et al． Novel mycophenolic adenine bis ( phosphonate) analogues as potential differentiation agents against human leukemia 1［J］． J Med Chem，2002， 45( 3) : 703 － 712．[16] KIM M S，BLAKE M，BAEK J H，et al． Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA［J］． Cancer Res， 2003， 63( 21) : 7291 － 7300．[17] CHEN P C，PATIL V，GUERRANT W， et al． Synthesis and structureactivity relationship of histone
環(huán)評公示相關(guān)推薦
鄂ICP備17016276號-1